Head-to-head · Cost-Efficiency Index
NuBloom vs Vea Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
NuBloom
Cost-first shoppers who want a physician-founded, whole-person GLP-1 program for women, in the 49 states it publishes as covered.
Visit NuBloomVea Health
Shoppers comfortable completing a full intake before seeing any price, in exchange for a broader microdosing menu.
Visit Vea HealthThe verdict
NuBloom and Vea Health tie on the Cost-Efficiency Index at 54/100, so neither wins outright on the numbers. For most shoppers we'd start with NuBloom (ranked #361, a hair above #366) — Cost-first shoppers who want a physician-founded, whole-person GLP-1 program for women, in the 49 states it publishes as covered. But Vea Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs NuBloom.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | NuBloom | Vea Health |
|---|---|---|
| Cost-Efficiency Index | 54/100 | 54/100 |
| Semaglutide / mo | Not disclosed | Not disclosed |
| Tirzepatide / mo | $249/mo (microdose tier, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | — | — |
| Tirzepatide / yr (modeled) | $2,988 | — |
| Coverage | 49 states | All 50 states |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #361 | #366 |
NuBloom
54/100Where the value is
- Transparent, openly published starting pricing: semaglutide $149/mo, tirzepatide $279/mo, with a cheaper $249/mo microdose tirzepatide option
- Founded and medically led by a named, identifiable physician (Dr. Marianne Pinkston Mueller)
- Full state-coverage list published and independently countable: 49 states, all except Mississippi
The tradeoffs
- Compounding pharmacy partner is never named anywhere on the site — only 'a state-licensed sterile compounding pharmacy partner'
- NuBloom's own independent LegitScript status isn't distinctly confirmed; the certification language attaches to its telehealth-platform partner, Telegra
Vea Health
54/100Where the value is
- Verified LegitScript certification with a working checker link (seal ID 48955268)
- Offers a genuine microdosing tier for both semaglutide and tirzepatide alongside the standard dose
- Repeats the FDA compounded-medication disclaimer on every page, and states 'Provider approval required. Not all patients qualify' rather than implying automatic approval
The tradeoffs
- Zero pricing is published anywhere on the public site — the entire catalog is gated behind the intake quiz
- No compounding pharmacy is named anywhere; the site only says 'domestic, pharmacy-grade suppliers' and 'FDA-registered, cGMP-certified facilities'
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.